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Abstract 
Background: Diabetic retinopathy (DR) is the major cause of blindness among working age adults. The aim of the 
study was to investigate risk factors for development of DR.
Methods: A case–control study was performed based on data from 240 individuals (80 cases and 160 controls) 
attending the Outpatient Specialty Clinic of the University of South Santa Catarina (UNISUL), between Mar/2010 and 
May/2014. Data collection occurred through review of medical charts for presence or absence of DR, determined by 
an ophthalmologist. Study protocol included demographic characteristics, metabolic control, diabetes mellitus (DM) 
profile and comorbidities. Statistical analysis used Chi square test for qualitative variables and multivariate logistic 
regression analysis to select independent variables (SPSS®18.0 software). Odds ratio (OR) was used as measure of 
association. The study was approved by research ethics committee of UNISUL.
Results: Mean age of group case was 59.5 years with a slight female predominance. Gender, age, body mass 
index were not associated with outcome. Individuals with poor glycemic control were more likely to DR (OR 3.83; 
95 % CI 1.57–9.37). It was observed a positive relationship between duration of DM and DR, with higher chances in 
11–15 years of disease (OR 7.52, 95 % CI 3.03–18.68) and >15 years (OR 9.01, 95 % CI 3.58–22.66). Regarding comor-
bidities, only diabetic nephropathy showed higher chance for DR (OR 3.32; 95 % CI 1.62–6.79).
Conclusions: Diabetic patients after 10 years of disease with poor glycemic control and nephropathy have a higher 
chance of DR.
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Background
Worldwide, diabetic retinopathy (DR) is the leading 
cause of blindness among working age adults [1]. Esti-
mated prevalence remains around 34.6 % (approximately 
93 million individuals) and 10.2 % have an advanced stage 
of the disease [2]. The basic mechanisms by which diabe-
tes mellitus (DM) generates microvascular complications 
are not fully elucidated. In fact, DR is a multifactorial dis-
ease and some studies reports the role of proinflamma-
tory cytokines and angiogenesis stimulatory molecules 
in the pathogenesis of the disease, in addition to chronic 
inflammation and oxidative stress caused by leukocytes 
[3, 4].
Under normal conditions, retinal capillaries have mural 
cells, known as pericytes, which are responsible for the 
regulation of vascular caliber and control of the blood 
flow of retinal microcirculation. These cells found to be 
important in the disease development, since they are lost 
in the early stages of DR [5–7]. However, not only peri-
cytes are affected by the disease. DR involves all of the 
retinal cellular elements, including glial cells, neurons, 
bipolar cells, amacrine cells and glanglion cells [8].
Recent studies reported that early signs of neuroretinal 
damage may even precede vascular signs of DR [9–13]. 
Rodrigues et  al. [12], using spectral-domain optical 
coherence tomography (SD-OCT), demonstrated thin-
ning in thickness of retinal nerve fiber layer in patients 
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with DM without DR compared to controls. Neverthe-
less, the clinical significance of these outcomes should be 
investigated and whether they represent a target in diabe-
tes treatment to prevent DR [12, 13].
Another key point for the development of vascular 
lesions is the capillary basement membrane thickening 
as a result of hyperglycemia, increased synthesis of base-
ment membrane components and other factors. This 
thickening of the basement membrane is related to excess 
vascular permeability that leads to leaky vessels, compro-
mised tight-junctions and increased vesicular transport 
[14]. Additionally, the role of genetic factors and their 
relationship with the pathogenesis of DR are being exten-
sively studied, including the epigenetic mechanisms such 
as DNA methylation, histone modifications in chromatin 
and noncoding RNAs [15].
Although major risk factors—hyperglycemia and 
hypertension—are extensively studied and show a strong 
association with DR [16, 17], there are variations in con-
sistency and pattern of these factors [2]. Some studies 
indicate that prolonged DM duration is indeed a well-
established risk factor for DR [18–20]. Regarding micro-
albuminuria, studies report its association as a marker 
of microvascular dysfunction and DR [21, 22], however 
further studies are needed to confirm this relationship 
[21]. Other risk factors such as body mass index (BMI) 
show controversies in relation to its association with this 
disease [23]. The aim of this study was to investigate risk 
factors for DR.
Methods
A case–control study was performed at the Outpatient 
Specialty Clinic of the University of South Santa Catarina 
(UNISUL) in Tubarão city, located in southern Brazil. 
Medical records of diabetic patients seen between March 
2010 and May 2014 were analyzed. Cases and controls 
corresponded to recordings of patients with DR and 
without DR, respectively. The control group sample was 
calculated by OpenEpi® (Open Source Epidemiologic 
Statistics for Public Health Version 2.3.1) with a 95  % 
confidence interval, power of 80  %, ratio of controls to 
cases: 2:1 and percentage of controls exposed to poor gly-
cemic control: 46 % [24] and Odds ratio 2.23 [19]. Added 
10  % for losses, sample calculation resulted in 86 cases 
and 170 controls.
Data was collected using a questionnaire especially 
developed for this research and included: presence or 
absence of DR, demographic data (gender and age), 
metabolic control (BMI and glycemic control), DM pro-
file (diabetes duration, type of DM and insulin use) and 
comorbidities (hypertension, dyslipidemia, and dia-
betic nephropathy). Clinical charts were first selected 
for the presence or absence of DR, determined by an 
ophthalmologist according to clinical findings confirmed 
by direct and indirect ophthalmoscopy following the clas-
sification of the international clinical diabetic retinopathy 
disease severity scale [25]. This study included records of 
all diabetic patients attended in the study period and they 
were all examined by an ophthalmologist. Patients with 
lens opacities and those in which the pupil dilation could 
not be performed were excluded (pregnant, uncontrolled 
hypertension and suspected of narrow-angle glaucoma). 
All information was obtained from clinical charts and 
finally analyzed for the study variables.
Mean age was used as cutoff point, since the sam-
ple showed a normal distribution. It was established 
the target for glycemic control the glycated hemoglobin 
(HbA1c) ≤7.0 % [26]. Regarding comorbidities, diagnosis 
was entirely based on clinical charts, considering previ-
ous clinical history and laboratory tests. Hypertension 
was set as blood pressure ≥140/90  mmHg (in distinct 
measures during the outpatient care) or use of antihy-
pertensive therapy [26]; dyslipidemia set as triglycerides 
≥150 mg/dL and total cholesterol ≥200 mg/dL or use of 
statins for dyslipidemia [16]; diabetic nephropathy set 
as microalbuminuria 30–300  mg/L, macroalbuminuria 
>300 mg/L or previous diagnosis of disease [26].
Statistical analysis was performed by a commercially 
available statistical software package (SPSS for Windows, 
version 18.0, SPSS, Chicago, IL, USA) and involved con-
struction of frequency distributions, verifying the pres-
ence of association between variables and outcome, using 
Chi square test for qualitative variables. Multivariate 
analysis was performed using logistic regression and the 
model included variables that showed effect with p < 0.20 
in bivariate analysis, except for gender and age that are 
classically part of models. The significance was calculated 
using Wald test and Odds ratio (OR) was used as the 
measure of association (p < 0.05). This study was based 
on the Resolution 466/12 of the National Health Council 
and was approved by the Ethical Committee of UNISUL. 
Researchers declare no conflicts of interest.
Results
A total of 240 medical records were included, 80 cases 
and 160 controls. Eighteen records were excluded; 14 for 
incomplete data associated to variables of interest and 04 
charts for impossibility of fundoscopy due to cataract.
Descriptive analysis resulted in average age of 
59.5 years for cases and 59.3 years for controls. The per-
centage of female patients was 63.75  % in both groups. 
The age group >60 years was observed in 51.25 % of cases 
and 48.12 % of controls.
Gender, age and BMI were not associated with higher 
chances of DR. Concerning glycemic control, it was 
observed that individuals with poor glycemic control had 
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a chance of 3.83 (95  % CI 1.57–9.37) for DR (Table  1). 
Similarly, diabetes duration was significantly associated 
with development of DR. It was observed a positive rela-
tionship between duration of DM and DR, with higher 
chances in 11–15  years of disease (OR 7.52, 95  % CI 
3.03–18.68) and >15 years (OR 9.01, 95 % CI 3.58–22.66) 
(Table 1). Regarding type of diabetes, our results demon-
strated a chance of 2.37 (95 % CI 0.52–10.68) for DR in 
type 1 DM, but this association did not reach statistical 
significance (p = 0.261) (Table 1).
In bivariate analysis, it was found association between 
DR and HbA1c >7  %, duration of DM ≥11  years and 
insulin use. After logistic regression, insulin use lost asso-
ciation, while other variables (glycemic control and dura-
tion of DM) remained associated with DR, regardless 
other variables included in the model (Table 1).
Multivariate analysis of comorbidities showed a chance 
to DR in patients with diabetic nephropathy of 3.32 (95 % 
CI 1.62–6.79) (Table  2). Other comorbidities studied, 
hypertension and dyslipidemia, did not reach the statisti-
cal significance level established (p < 0.05).
Discussion
Descriptive analysis of demographic characteristics 
in both groups presented a similar mean age (59.5 vs 
59.3 years, cases and controls respectively) with a slight 
predominance of females. In qualitative analysis, the var-
iables age and gender were not associated with a greater 
chance of DR. Similarly, in several studies, no associa-
tion was found between DR and gender, age or age group 
[27–31]. However, some reports have found an inde-
pendent association in males [18, 32, 33], while a his-
torical cohort of Kajiwara et  al. [34], presented greater 
chance of DR among females. Yet, in disagreement with 
the present study, Al-Sarraf et al. [35] observed a greater 
chance of DR in individuals aged 50–59  years (OR 2.2, 
95 % CI 1.1–5.2) and ≥60 years (OR 4.6, 95 % CI 11.0–
2.0). Present findings show that probably age and gender 
Table 1 Cases and controls according to demographic characteristics, metabolic control and diabetes mellitus profile
ORb: Odds-ratio Brut, ORAdj: adjusted Odds-ratio
* p < 0.05; ** p < 0.01 (Pearson’s Chi square test and Wald test)
† 95 % of confidence interval Brut; ‡ 95 % adjusted confidence interval
Total (240) Diabetic retinopathy ORb CIb† ORAdj CIAdj‡
Yes (80) No (160)
n n % n %
Gender
 Female 153 51 33.3 102 66.7 1.00 0.57–1.74 1.13 0.57–2.26
 Male 87 29 33.3 58 66.7 1 1
Age (years)
 ≤60 122 39 32.0 83 68.0 1 1
 >60 118 41 34.7 77 65.3 1.13 0.66–1.93 1.28 0.64–2.56
BMI
 18.5–24.9 39 13 33.3 26 66.7 1.09 0.51–2.35 – –
 25–30 70 26 37.1 44 62.9 1.29 0.70–2.38 – –
 >30 131 41 31.3 90 68.7 1 – –
Glycemic control (%)
 HbA1c ≤ 7 80 10 12.5 70 87.5 1 1
 HbA1c > 7 160 70 43.8 90 56.3 5.43** 2.61–11.36 3.83* 1.57–9.37
Diabetes duration (years)
 <5 87 14 16.1 73 83.9 1 1
 6–10 67 14 20.9 53 79.1 1.37 0.61–3.13 2.05 0.71–5.92
 11–15 26 12 46.2 14 53.8 4.46* 1.71–11.63 7.52** 3.03–18.68
 >15 60 40 66.7 20 33.3 10.42** 4.76–22.73 9.01** 3.58–22.66
Type of diabetes
 Type 1 11 6 54.5 5 45.5 2.51 0.74–8.50 2.37 0.52–10.68
 Type 2 229 74 32.3 155 67.7 1 1
Insuline use
 Yes 112 52 46.4 60 53.6 3.09** 1.76–5.41 1.25 0.61–2.57
 No 128 28 21.9 100 78.1 1 1
Page 4 of 7Lima et al. Int J Retin Vitr  (2016) 2:21 
are not risk factors for DR. Therefore, regular moni-
toring of these patients must be done regardless these 
variables.
Among metabolic control factors, none of BMI catego-
ries revealed higher chances to DR. Literature differs in 
this question and demonstrates a controversy with this 
association, especially about type 2 DM [23]. Several 
studies show no association between BMI and DR [18, 
21, 31, 36–39] and other positive association [34, 40, 41]. 
Ahmed et al. [28], in a follow-up of involving 977 type 2 
DM during 5, 10 and 15 years, did not find an increased 
risk of DR in any of categories studied. Yoshida et  al. 
[42] presented statistical significance in DR frequencies 
in patients with BMI  >  23.7  kg/m2 only after 7  years of 
follow-up. Our findings appear to corroborate the results 
reported in other studies and BMI does not seem to have 
direct relationship with development of DR.
Regarding glycemic control, individuals with HbA1c 
>7  % were more likely to develop DR. Chronic hyper-
glycemia is responsible for a chain of events that leads 
to DR [43] and glycemic control one of the key points 
of primary prevention for this complication [29, 44, 45]. 
Strong evidences indicate an adequate glycemic control 
in levels of HbA1c ≤7 % as a reducer of risk for DR, both 
in type 1 DM and in type 2 DM [32, 46, 47]. Accordingly 
to a longitudinal study [28], there was an association 
between DR and poor glycemic control showing higher 
OR for intervals of 5, 10 and 15  years of 8.34, 3.45 and 
4.9, respectively. In the present study, inadequate control 
of blood glucose levels proved to be an important factor 
for DR. After diagnosis of DM, patients must reach the 
targets for control of glycemia, reducing the chances of 
visual impairment.
Duration of DM, an important predictor DR, deter-
mines the exposure time of other risk factors [48]. In the 
current study, after 10  years of disease, results showed 
high association. Al-Sarraf et al. [35] noticed that patients 
with 10–19 years of disease are twice as likely to have DR 
and approximately three times more when the exposure 
is more than 20 years. According to a recent study, con-
ducted in United States of America [18], each year of DM 
represents a 6 % increase in chance of DR. This correla-
tion with duration of diabetes was first demonstrated in 
the Wisconsin epidemiologic study of diabetic retinopa-
thy (WESDR) [49], with a higher prevalence in 25, 60 and 
80 % for 5, 10 and 15 years of evolution of DM, respec-
tively. In addition to aforementioned, several other stud-
ies, show statistical significance for this factor, both in 
type 1 DM and in type 2 DM [27, 29, 30, 36, 37], perhaps 
the most important independent risk factor for DR [31, 
50, 51].
Type of DM was not considered a risk factor for DR. 
Similarly, in a multicenter study in Kuwait, Al Sarraf et al. 
[35] found no significant results when comparing same 
variables. However, WESDR, in 25 years of follow-up of 
type 1 DM subjects, demonstrated cumulative incidence 
rates of 97  % for DR [52]. The authors suggest that the 
lack of association probably occurred due to small num-
ber of DM type 1 individuals in the study’s sample.
Concerning insulin therapy, an interesting finding was 
observed. In bivariate analysis, patients using insulin 
presented a highly significant chance of DR. In multi-
variate analysis, odds for DR lost statistical significance 
and strength of association. Furthermore, Yang et  al. 
[29] found no statistically significant after multivariate 
analysis (OR 1.65, 95 % CI 0.80–3.38). On the other hand, 
Table 2 Cases and controls according to comorbidities
ORb: Odds-ratio Brut, ORAdj: adjusted Odds-ratio
* p < 0.05; ** p < 0.01 (Pearson’s Chi square test and Wald test)
† 95 % of confidence interval Brut; ‡ 95 % adjusted confidence interval
Total (260) Diabetic retinopathy CIb† ORb CIAdj‡ ORAdj
Yes (80) No (160)
n n % n %
Hypertension
 Yes 204 71 34.8 133 65.2 1.60 0.71–3.59 – –
 No 36 9 25.0 27 75.0 1 – –
Dyslipidemia
 Yes 176 66 35.8 112 64.2 1.54 0.81–2.90 1.41 (0.61–3.25)
 No 64 17 26.6 47 73.4 1 – –
Diabetic nephropathy
 Yes 69 39 56.5 30 43.5 4.12** 2.28–7.44 3.32* (1.62–6.79)
 No 171 41 24.0 130 76.0 1
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some studies have shown significantly higher chances 
in diabetics treated with insulin, OR 3.23 [21] and OR 
3.51 [8], but only included individuals aged above 40 and 
67 years, respectively. One of the most important studies 
on the subject, the United Kingdom Prospective Diabe-
tes Study [47], suggested that adequate and continuous 
glycemic control inhibits development of DR, regardless 
the method of treatment. Other major study, the Dia-
betes Control and Complications Trial (DCCT), found 
that intensive insulin treatment reduces the risk of devel-
opment of DR and slows the progression of clinically 
important retinopathy. In patients without retinopathy at 
enrollment, the 3-year risk of developing retinopathy was 
reduced by 75 % in the intensive insulin treatment group 
compared to the conventional treatment group [53].
In the present study, the authors suggest that prob-
ably the absence of significance between insulin use and 
DR occurred as a reflection of reverse causality bias. In a 
similar way, the WESDR observed no higher relative risk 
for DR with insulin use among patients >30  years [49]. 
Yoshida et al. [42], found that change of therapy method 
modifies incidence rate of DR and argued that individu-
als under insulin therapy experience a more severe met-
abolic deterioration, not being probably insulin use an 
isolated risk factor for this diabetic complication.
About blood pressure, even in absence of established 
hypertension, changes in homeostasis of blood pres-
sure levels appear to be associated with DR [23]. In a 
study with diabetic over 67  years [21], the association 
between higher levels of systolic pressure and DR at any 
stage occurred, but in agreement with the present study, 
hypertension as a comorbidity was not an independent 
risk factor for DR, as well as in other studies [29, 31, 36, 
54]. Nevertheless, Zheng [54] concluded that the rela-
tionship between these two variables cannot be excluded, 
since isolated pressure measurements may not accurately 
represent continued effect of high pressure. In agree-
ment, some studies indicate hypertension as one of the 
most important risk factors in the development of DR 
[50, 51, 55, 56].
Many researchers have shown that the relationship 
between serum lipids and DR does not seem consistent 
or loses association after adjustment for confounding 
factors [27–30, 37]. The Beijing Eye Study [36] reported 
no association between increased cholesterol levels and 
DR. Thus, lipid changes do not appear to be the main 
responsible for microvascular involvement. Even though, 
in the current study, dyslipidemia have not been associ-
ated with DR, the importance of diet quality of patients 
cannot be underestimated. Moreover, in addition to gly-
cemic control, HbA1c and lipid profile investigations are 
recommended to continue as routine when we are han-
dling these patients [57].
Microvascular complications such as diabetic neuropa-
thy and DR can be correlated and they usually follow 
with the onset of diabetic nephropathy, which suggests a 
strong association between them [23, 58]. Jost et al. [27], 
after logistic regression revealed a chance of 3.24 (95 % CI 
1.04–10.04) for DR in patients with diabetic nephropathy. 
Rajalakshmi et  al. [37] observed a significant presence 
of microalbuminuria in both type 1 DM and type 2 DM 
individuals with early diagnosis of DM (p  =  0.001 and 
p = 0.009, respectively). Studies indicate that the damage 
to the small blood vessels share the same pathogenesis, 
part of a systemic microvascular dysfunction [59, 60].
The strengths of this study allowed the validation of 
results obtained. First, information sources showed an 
excellent quality because patient records were complete 
and properly filled. Second, it is an outpatient specialty 
clinic with adequate infrastructure for care and for 
monitoring of patients that maximizes the formation of 
representative groups of cases and controls. Third, we 
undertook methodological efforts to enable scientific 
comparability using multivariate data analysis in order 
to reduce confusing factors. Fourth, it highlights a sig-
nificant population problem and there is no major epide-
miological study in Brazil about this topic. Therefore, our 
study amplifies the comparability of data regarding the 
reality of DR in Brazil.
In addition to its strengths, there are some limita-
tions in the present study. It was not possible to perform 
more accurate tests, such as fluorescein angiography or 
SD-OCT, for all cases and controls. Consequently, some 
patients with DR could have been inadvertently excluded 
from this study. Moreover, since it is a chart review cri-
teria of time of disease may have been inaccurate, how-
ever considering the fact that these patients had a longer 
time of disease before the diagnoses it only generates an 
underestimation of data. Lastly, we could not estimate 
specific OR for each variable of individuals with type 1 
and type 2 DM individually, since the sample was mainly 
composed of type 2 DM individuals.
Conclusions
According to our results, diabetic patients after 10 years 
of disease with poor glycemic control and nephropathy 
have a greater chance of DR. The mechanisms underlying 
DR development are not fully elucidated. Thus, the sci-
entific publication in this area should intensify, especially 
in Brazil, to improve prevention, identify risk groups and 
establish real modifiable factors of this highly prevalent 
disease.
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